WHITE PAPER
Discover novel digital assessments being developed to validate digital biomarkers in PD and how they can be applied in clinical trials.
Digital biomarkers provide real-time data on patients’ physiology and disease progression to help researchers better understand treatment efficacy.
Leading the way in digital biomarkers technology, Clinical ink offers the best-in-class analytics platform to capture, collect, and interpret real-time data powering the evaluation and development of new treatments.
Discover novel digital assessments being developed to validate digital biomarkers in PD and how they can be applied in clinical trials.
Digital biomarkers are objective, quantifiable physiological and behavioral data that are collected and measured by digital devices such as smartphones, wearables, or sensors. They can provide insights into patients' health status, treatment response, and disease progression, enabling more personalized and timely therapeutic decisions.
Digital biomarkers offer several key benefits to clinical trial design and processes:
Â
The Clinical ink platform supports a wide variety of digital biomarkers, including physiological metrics like heart rate, behavioral indicators like activity levels, patient-reported outcomes, and specialized health indicators. The flexibility of the platform ensures the collection of relevant and meaningful data for diverse clinical research solutions.
Sales and Solutions
Direct   1.336.464.0697
Support
Toll-Free 1.800.301.5033
Direct   1.336.464.0697
Insert HTML text here.
Progress in a New Era: Digital Biomarkers as Endpoints in Parkinson’s Disease
Discover novel digital assessments being developed to validate digital biomarkers in PD and how they can be applied in clinical trials.
Request more information, submit questions, set up a demonstration, and more.